Metropolitan Life Insurance CO Kodiak Sciences Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$3.01 - $7.45 $2,103 - $5,207	699 New	699 $3,000
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $952 - $1,758	-198 Reduced 9.7%	1,844 $11,000
Q4 2022 Jun 14, 2023	BUY	$6.52 - $8.05 $1,290 - $1,593	198 Added 10.74%	2,042 $14.6 Million
Q3 2022 Jun 14, 2023	BUY	$7.57 - $12.5 $1,498 - $2,475	198 Added 10.74%	2,042 $15.8 Million
Q2 2022 Jun 20, 2023	BUY	$5.04 - $9.48 $997 - $1,877	198 Added 10.74%	2,042 $15,000
Q1 2022 Jun 20, 2023	BUY	$7.09 - $89.45 $1,403 - $17,711	198 Added 10.74%	2,042 $15,000
Q1 2022 Mar 30, 2023	SELL	$7.09 - $89.45 $47,361 - $597,526	-6,680 Reduced 76.59%	2,042 $15,000
Q1 2022 May 12, 2022	SELL	$7.09 - $89.45 $47,361 - $597,526	-6,680 Reduced 76.59%	2,042 $16,000
Q4 2021 Jun 21, 2023	BUY	$80.85 - $128.49 $556,086 - $883,754	6,878 Added 372.99%	8,722 $739,000
Q4 2021 Mar 30, 2023	SELL	$80.85 - $128.49 $43,012 - $68,356	-532 Reduced 5.75%	8,722 $739,000
Q4 2021 Feb 15, 2022	SELL	$80.85 - $128.49 $43,012 - $68,356	-532 Reduced 5.75%	8,722 $739,000
Q3 2021 Jun 21, 2023	BUY	$81.97 - $106.94 $607,397 - $792,425	7,410 Added 401.84%	9,254 $888,000
Q2 2021 Jun 21, 2023	BUY	$77.2 - $126.54 $572,052 - $937,661	7,410 Added 401.84%	9,254 $860,000
Q2 2021 Mar 30, 2023	BUY	$77.2 - $126.54 $47,478 - $77,822	615 Added 7.12%	9,254 $860,000
Q2 2021 Aug 16, 2021	BUY	$77.2 - $126.54 $713,714 - $1.17 Million	9,245 Added 102722.22%	9,254 $861,000
Q1 2021 Jun 26, 2023	BUY	$110.45 - $164.47 $750,507 - $1.12 Million	6,795 Added 368.49%	8,639 $980 Million
Q1 2021 Mar 30, 2023	SELL	$110.45 - $164.47 $32,693 - $48,683	-296 Reduced 3.31%	8,639 $979,000
Q1 2021 May 14, 2021	SELL	$110.45 - $164.47 $985,876 - $1.47 Million	-8,926 Reduced 99.9%	9 $980,000
Q4 2020 Jun 22, 2023	BUY	$60.78 - $154.03 $430,990 - $1.09 Million	7,091 Added 384.54%	8,935 $1.31 Million
Q4 2020 Mar 30, 2023	BUY	$60.78 - $154.03 $23,096 - $58,531	380 Added 4.44%	8,935 $1.31 Million
Q4 2020 Feb 16, 2021	BUY	$60.78 - $154.03 $23,096 - $58,531	380 Added 4.44%	8,935 $1.31 Million
Q3 2020 Jun 26, 2023	BUY	$45.05 - $59.27 $302,330 - $397,760	6,711 Added 363.94%	8,555 $506,000
Q2 2020 Jun 26, 2023	BUY	$42.74 - $66.25 $286,828 - $444,603	6,711 Added 363.94%	8,555 $462,000
Q1 2020 Jul 12, 2023	BUY	$38.18 - $73.95 $256,225 - $496,278	6,711 Added 363.94%	8,555 $408,000
Q1 2020 Mar 30, 2023	BUY	$38.18 - $73.95 $44,174 - $85,560	1,157 Added 15.64%	8,555 $408,000
Q1 2020 May 15, 2020	BUY	$38.18 - $73.95 $44,174 - $85,560	1,157 Added 15.64%	8,555 $408,000
Q4 2019 Jul 12, 2023	BUY	$13.9 - $76.65 $77,200 - $425,714	5,554 Added 301.19%	7,398 $532,000
Q4 2019 Mar 30, 2023	SELL	$13.9 - $76.65 $23,755 - $130,994	-1,709 Reduced 18.77%	7,398 $532,000
Q4 2019 Feb 14, 2020	SELL	$13.9 - $76.65 $23,755 - $130,994	-1,709 Reduced 18.77%	7,398 $532,000
Q3 2019 Jul 12, 2023	BUY	$10.24 - $17.57 $74,373 - $127,610	7,263 Added 393.87%	9,107 $130,000
Q3 2019 Mar 30, 2023	BUY	$10.24 - $17.57 $72,345 - $124,132	7,065 Added 345.98%	9,107 $130,000
Q3 2019 Nov 14, 2019	BUY	$10.24 - $17.57 $93,255 - $160,009	9,107 New	9,107 $131,000
Q2 2019 Jul 12, 2023	BUY	$6.2 - $12.0 $880 - $1,704	142 Added 7.7%	1,986 $23.2 Million

Others Institutions Holding KOD

# of Institutions

Shares Held

39M

Call Options Held

6.5K

Put Options Held

5.8K

Baker Bros. Advisors LP New York, NY

17.3M
Shares

$151 Million
0.48% of portfolio
Black Rock Inc. New York, NY

3.85M
Shares

$33.7 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.95M
Shares

$17.1 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

1.69M
Shares

$14.7 Million
0.0% of portfolio
Iconiq Capital, LLC San Francisco, CA

1.02M
Shares

$8.9 Million
0.06% of portfolio

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account